Keros to receive $20M Takeda milestone after first patient dosed in Phase 3 ELRiSE MF trial

Keros Therapeutics, Inc.

Keros expects a $20M development milestone from Takeda after the first patient was dosed in ELRiSE MF, a Phase 3 trial of elritercept vs placebo in myelofibrosis with anemia on ruxolitinib.
The Takeda license, effective January 16, 2025, covers development, manufacturing, and commercialization of elritercept worldwide excluding mainland China, Hong Kong, and Macau.
Keros received a $200M upfront cash payment in February 2025 and can earn development, commercial, and sales milestones potentially exceeding $1.1B plus tiered royalties.
Keros plans to distribute 25% of net cash proceeds from the $20M milestone to stockholders following receipt.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.